DPYD genotyping and 5-fluoropyrimidine toxicity: An overview of systematic reviews protocol
Farm Hosp. 2023 Sep 25:S1130-6343(23)00693-1. doi: 10.1016/j.farma.2023.08.009. Online ahead of print.ABSTRACTINTRODUCTION: The increased risk of severe and life-threatening toxicity in patients with dihydropyridine dehydrogenase (DPD) deficiency, under treatment with fluoropyrimidines, has been widely studied. An up-to-date overview of systematic reviews summarizing existing literature can add value by highlighting most relevant information and supports decision-making regarding treatment in DPD deficient patients. The main objective of this overview of systematic reviews is to identify published systematic reviews on the...
Source: Farmacia Hospitalaria - September 27, 2023 Category: Drugs & Pharmacology Authors: Sara Otero Torres Olalla Montero P érez Rosa Rodr íguez Mauriz Eduard Fort Casamartina Sandra Fontanals Mart ínez Ana Clop és Estela Source Type: research
Persistence, current state of the art
Farm Hosp. 2023 Sep 25:S1130-6343(23)00122-8. doi: 10.1016/j.farma.2023.07.015. Online ahead of print.NO ABSTRACTPMID:37758639 | DOI:10.1016/j.farma.2023.07.015 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - September 27, 2023 Category: Drugs & Pharmacology Authors: Misael Rodriguez Goicoechea Eduardo Tejedor Tejada Joaqu ín Borrás Blasco Source Type: research
[Translated article] Deglufarm: Mobile application with recommendations for the safe administration of drugs in patients with dysphagia or swallowing disorders
CONCLUSIONS: Deglufarm® is an easy tool to consult, with the most current evidence on handling the medicines it contains.PMID:37758640 | DOI:10.1016/j.farma.2023.08.002 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - September 27, 2023 Category: Drugs & Pharmacology Authors: Eva Delgado-Silveira Patricia Bravo Jos é Mar ía Teresa Llanos García Elena Alba Álvaro Alonso Mar ía Muñoz García Francisco Jos é Hidalgo Correas Source Type: research
Analysis 2016-2021 of the development of the MAPEX outpatient pharmaceutical care Project by regions in Spain
CONCLUSIONS: The implementation and development of the MAPEX initiatives has had a positive impact on the evolution in all healthcare areas of pharmaceutical care for outpatients. The situation survey makes it possible to identify by regions the significant points for improvement, as well as those areas to be developed through strengthening and corrective actions. The expansion of the project in the coming years will mean progress towards excellence in care and in the improvement of health results.PMID:37749003 | DOI:10.1016/j.farma.2023.08.007 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - September 25, 2023 Category: Drugs & Pharmacology Authors: Esther Vicente-Escrig Pilar Taberner Bonastre Olatz Ibarra Barrueta Manuel Murillo Izquierdo Cecilia M Fern ández-Llamazares Ram ón Morillo-Verdugo Source Type: research
Analysis 2016-2021 of the development of the MAPEX outpatient pharmaceutical care Project by regions in Spain
CONCLUSIONS: The implementation and development of the MAPEX initiatives has had a positive impact on the evolution in all healthcare areas of pharmaceutical care for outpatients. The situation survey makes it possible to identify by regions the significant points for improvement, as well as those areas to be developed through strengthening and corrective actions. The expansion of the project in the coming years will mean progress towards excellence in care and in the improvement of health results.PMID:37749003 | DOI:10.1016/j.farma.2023.08.007 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - September 25, 2023 Category: Drugs & Pharmacology Authors: Esther Vicente-Escrig Pilar Taberner Bonastre Olatz Ibarra Barrueta Manuel Murillo Izquierdo Cecilia M Fern ández-Llamazares Ram ón Morillo-Verdugo Source Type: research
Risk-sharing agreement based on health outcomes for the treatment of moderate-severe psoriasis with certolizumab pegol
CONCLUSION: Our study shows that CZP is effective in real clinical practice in patients with moderate-severe plaque PsO, with an improvement in absolute PASI and DLQI, as well as other scales, both for the total population and in the subgroups analyzed. Nearly 91% of patients reached the therapeutic target fixed in the RSA. Implementing this type of agreement can provide a direct or indirect benefit for all the agents involved in the process, providing valuable information for decision-making.PMID:37739901 | DOI:10.1016/j.farma.2023.07.016 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - September 22, 2023 Category: Drugs & Pharmacology Authors: Andr és Navarro Ruiz Fernando Toledo Alberola Susana Aceituno Grupo ARCODERM Source Type: research
Risk-sharing agreement based on health outcomes for the treatment of moderate-severe psoriasis with certolizumab pegol
CONCLUSION: Our study shows that CZP is effective in real clinical practice in patients with moderate-severe plaque PsO, with an improvement in absolute PASI and DLQI, as well as other scales, both for the total population and in the subgroups analyzed. Nearly 91% of patients reached the therapeutic target fixed in the RSA. Implementing this type of agreement can provide a direct or indirect benefit for all the agents involved in the process, providing valuable information for decision-making.PMID:37739901 | DOI:10.1016/j.farma.2023.07.016 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - September 22, 2023 Category: Drugs & Pharmacology Authors: Andr és Navarro Ruiz Fernando Toledo Alberola Susana Aceituno Grupo ARCODERM Source Type: research
Risk-sharing agreement based on health outcomes for the treatment of moderate-severe psoriasis with certolizumab pegol
CONCLUSION: Our study shows that CZP is effective in real clinical practice in patients with moderate-severe plaque PsO, with an improvement in absolute PASI and DLQI, as well as other scales, both for the total population and in the subgroups analyzed. Nearly 91% of patients reached the therapeutic target fixed in the RSA. Implementing this type of agreement can provide a direct or indirect benefit for all the agents involved in the process, providing valuable information for decision-making.PMID:37739901 | DOI:10.1016/j.farma.2023.07.016 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - September 22, 2023 Category: Drugs & Pharmacology Authors: Andr és Navarro Ruiz Fernando Toledo Alberola Susana Aceituno Grupo ARCODERM Source Type: research
Abemaciclib as adjuvant treatment for high-risk early breast cancer
CONCLUSIONS: The results of the pivotal trial are sufficient to consider abemaciclib as adjuvant treatment for high-risk early breast cancer in highly selected patients. However, in order to the efficacy results present less uncertainty, we must wait for a evaluation later, in which we can have a mature determination at 3 years (with more patients at risk).PMID:37735004 | DOI:10.1016/j.farma.2023.08.006 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - September 21, 2023 Category: Drugs & Pharmacology Authors: Ganfornina Andrades Ana F énix Caballero Silvia Salguero Olid Alba Alegre Del-Rey Emilio Jes ús Source Type: research
[Translated article] Implementation of the standardized process of drug therapy evaluation in inpatients and outpatients
CONCLUSIONS: This study shows a clinical pharmacist developed tool called SPEP that increased the pharmacist evaluation and pharmacist interventions number in multiple clinical scenarios. These were significant only in critical care patients. Future investigations should make effort to evaluate the quality and clinical impact of these interventions.PMID:37735005 | DOI:10.1016/j.farma.2023.06.003 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - September 21, 2023 Category: Drugs & Pharmacology Authors: A Gonz ález W Guti érrez T Fuenzalida F Lizana M Guti érrez N Severino Source Type: research
Abemaciclib as adjuvant treatment for high-risk early breast cancer
CONCLUSIONS: The results of the pivotal trial are sufficient to consider abemaciclib as adjuvant treatment for high-risk early breast cancer in highly selected patients. However, in order to the efficacy results present less uncertainty, we must wait for a evaluation later, in which we can have a mature determination at 3 years (with more patients at risk).PMID:37735004 | DOI:10.1016/j.farma.2023.08.006 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - September 21, 2023 Category: Drugs & Pharmacology Authors: Ganfornina Andrades Ana F énix Caballero Silvia Salguero Olid Alba Alegre Del-Rey Emilio Jes ús Source Type: research
[Translated article] Implementation of the standardized process of drug therapy evaluation in inpatients and outpatients
CONCLUSIONS: This study shows a clinical pharmacist developed tool called SPEP that increased the pharmacist evaluation and pharmacist interventions number in multiple clinical scenarios. These were significant only in critical care patients. Future investigations should make effort to evaluate the quality and clinical impact of these interventions.PMID:37735005 | DOI:10.1016/j.farma.2023.06.003 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - September 21, 2023 Category: Drugs & Pharmacology Authors: A Gonz ález W Guti érrez T Fuenzalida F Lizana M Guti érrez N Severino Source Type: research
[Translated article] Consensus recommendations on the preventive treatment of migraine
CONCLUSIONS: The high degree of consensus indicates that the opinion of neurologists and hospital pharmacists on the role of anti-Calcitonin Gene-related Peptide monoclonal antibodies in the preventive treatment of migraine is very similar and allows identifying those controversies that still exist, to improve the care and follow-up of patients with migraine.PMID:37730507 | DOI:10.1016/j.farma.2023.07.002 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - September 20, 2023 Category: Drugs & Pharmacology Authors: Miguel Ángel Calleja-Hernández Ángel Luis Guerrero-Peral Pablo Irimia-Sieira Ic íar Martínez-López Sonia Santos-Lasaosa Maite Sarobe-Carricas Jos é María Serra López-Matencio Jos é Miguel Láinez-Andrés Source Type: research
[Translated article] Consensus recommendations on the preventive treatment of migraine
CONCLUSIONS: The high degree of consensus indicates that the opinion of neurologists and hospital pharmacists on the role of anti-Calcitonin Gene-related Peptide monoclonal antibodies in the preventive treatment of migraine is very similar and allows identifying those controversies that still exist, to improve the care and follow-up of patients with migraine.PMID:37730507 | DOI:10.1016/j.farma.2023.07.002 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - September 20, 2023 Category: Drugs & Pharmacology Authors: Miguel Ángel Calleja-Hernández Ángel Luis Guerrero-Peral Pablo Irimia-Sieira Ic íar Martínez-López Sonia Santos-Lasaosa Maite Sarobe-Carricas Jos é María Serra López-Matencio Jos é Miguel Láinez-Andrés Source Type: research
[Translated article] Medication reconciliation in pediatric hemato-oncologic patients: A multicenter study
CONCLUSIONS: In order to avoid or reduce errors in one of the critical safety points such as transitions of care, there are measures such as medication reconciliation. In the case of complex chronic pediatric patients, such as onco-hematological patients, the number of drugs as part of home treatment is the variable that has been associated with the presence of medication reconciliation errors on admission to hospital, and the omission of some medication was the main cause of these errors.PMID:37716875 | DOI:10.1016/j.farma.2023.07.012 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - September 16, 2023 Category: Drugs & Pharmacology Authors: Margarita Cuervas-Mons Vendrell Dolores Pilar Iturgoyen Fuentes Miquel Villaronga Flaque Maria Jos é Cabañas Poy Cecilia M Fern ández-Llamazares Concha Álvarez Del Vayo Carmen Gallego Fern ández Cristina Mart ínez Roca Yolanda Hern ández Gago Ana G Source Type: research
